Browse Reports

Getty Images Holdings, Inc. is a digital media company specializing in licensing a broad range of visual content, including third-party licensed and in-house created imagery. The company serves a global customer base through various licensing models and price points. Getty Images faces competitive pressures and operational risks including cybersecurity threats and regulatory compliance related to data privacy. The company maintains significant partnerships with major cultural and sporting events, supporting its content offerings. Financially, Getty Images reported a net loss in the most recent quarter but revenue growth for the full year 2025. The company holds substantial current assets but also has current liabilities exceeding current assets, resulting in a current ratio below 1 as of the end of 2025. Getty Images is an emerging growth company and regularly files detailed reports with the SEC.

FutureFuel Corp. is a Delaware-based manufacturer of inorganic chemicals, bio-based specialty chemicals, and biofuels, operating primarily through its subsidiary FutureFuel Chemical Company. The company’s integrated facility in Batesville, Arkansas, spans 2,200 acres and includes state-of-the-art manufacturing, laboratories, and advanced waste treatment infrastructure. FutureFuel’s operations are organized into two main segments: Chemicals and Biofuels. The Chemicals segment includes Custom Manufacturing of proprietary specialty chemicals under long-term contracts and Performance Chemicals sold to multiple customers. The Biofuels segment produces biodiesel with a demonstrated capacity of approximately 59 million gallons per year. The company holds ISO 9001 certification for quality management and BQ-9000 accreditation for biodiesel quality. FutureFuel emphasizes operational excellence, cost leadership, and integrated infrastructure to maintain competitive advantages. The company’s strategic focus includes expanding into regulated markets such as pharmaceutical intermediates and food-grade ingredients, customer diversification, and transitioning to full-service strategic partnerships. In 2025, the company faced significant revenue declines primarily due to regulatory uncertainty affecting biodiesel production and operational interruptions in the Chemicals segment. Despite these challenges, FutureFuel maintains strong liquidity and continues to invest in capital infrastructure to improve plant reliability.

Zomedica Corp. is a veterinary health company specializing in companion animal diagnostics and therapeutic medical devices. Its mission is to improve patient care and the economic health of veterinary practices by providing innovative products and technologies. The company has expanded its product portfolio and capabilities through acquisitions, including Structured Monitoring Products, Inc. and Qorvo Biotechnologies, LLC. Zomedica's product lines include diagnostic platforms such as TRUFORMA, which uses patented Bulk Acoustic Wave technology for rapid point-of-care testing, and therapeutic devices like Assisi and VETIGEL. The company operates manufacturing and distribution centers in Roswell, Georgia, and Plymouth, Minnesota, and sells products through direct sales, distributors, and online channels domestically and internationally. Zomedica's shares were delisted from NYSE American in March 2025 and now trade on OTCQB under the ticker ZOMDF.

Eagle Financial Services, Inc. is a bank holding company incorporated in 1991 and headquartered in Berryville, Virginia. It operates through its subsidiary, Bank of Clarke, which is chartered under Virginia law. The Bank operates 15 full-service branches, a loan production office, a wealth management office, and a drive-through facility, serving the Shenandoah Valley of Virginia, Northern Virginia, and Frederick, Maryland. The Bank offers a broad range of retail and commercial banking services including deposit accounts, consumer, mortgage and commercial loans, ATM and debit card services, and digital banking platforms. The Bank of Clarke Wealth Management Division provides fiduciary, trust, and brokerage services with a variety of investment products offered through third-party providers. The Company employs 254 full-time equivalent employees and has been certified as a Great Place to Work®. The Company operates in a highly regulated environment under the supervision of the Federal Reserve, Virginia State Corporation Commission, and FDIC, among others. The Bank faces significant competition from various financial institutions and fintech firms in its market area. The Company relies primarily on customer deposits for liquidity and growth, supplemented by borrowings if necessary. The loan portfolio is concentrated in real estate-secured loans, which represent over three-quarters of the portfolio. The Company manages credit risk through underwriting and allowance for credit losses. The Company is exposed to risks from interest rate fluctuations, inflation, cybersecurity threats, and rapid technological changes in the financial services industry.

Bumble Inc. is a technology company focused on online dating and social connections through its family of apps including Bumble, Badoo, Bumble For Friends, and BFF. The company’s mission is to bring people closer to love by enabling healthy and equitable relationships, with a platform designed to prioritize safety, inclusivity, and empowerment, especially for women. Bumble’s apps operate on a freemium model, offering free basic services with premium subscriptions and in-app purchases. The company continuously innovates its product offerings using AI and machine learning to improve matching algorithms and safety features. Bumble also engages in public policy advocacy and social impact initiatives related to online safety and women’s empowerment. As of the end of 2025, Bumble had approximately 3.6 million paying users across its apps and a diverse workforce of about 580 employees.

Xsolla SPAC 1 is a Cayman Islands-incorporated special purpose acquisition company that completed its IPO in January 2026, raising $200 million through the issuance of units consisting of Class A ordinary shares and redeemable warrants. The company is listed on Nasdaq under the ticker XSLL. As a SPAC, it currently holds funds in trust pending a business combination. The latest financial snapshot as of September 30, 2025, shows limited current assets relative to current liabilities and a net loss, reflecting early-stage financials without disclosed operating revenue.

Hammer Technology Holdings Corp., formerly Hammer Fiber Optics Holdings Corp., is a company focused on financial services technology, specifically through its HammerPay mobile payments platform. The company divested its telecommunications assets in late 2024 to focus on fintech initiatives. HammerPay is designed as a scalable, mobile-first platform offering digital stored value technology, prepaid merchant cards, and neo-banking services, targeting consumers and merchants in developing markets, particularly in Africa and diaspora payment channels. The company owns proprietary intellectual property supporting its fintech operations, including software, compliance infrastructure, and business processes. HammerPay competes with established fintech and payment processing companies but leverages its compliance rigor and scalable platform as competitive advantages. The company had no revenue as of early 2026, with ongoing investments in platform development and market expansion.

VitaNova Life Sciences Corp is a Nevada-incorporated company operating primarily in two segments: consulting services and healthcare products. The consulting segment offers advisory services in management, accounting, and finance to domestic and international clients. The healthcare segment markets anti-aging products designed to increase NAD+ levels, aiming to promote anti-aging effects and improve metabolic and cognitive functions. The company also provides personalized health consultation and customized wellness plans. Sales channels include e-commerce, physical stores, social media, and direct sales. The company emphasizes product innovation, brand development, and international market expansion. As of early 2026, the company maintains strong liquidity but reported a net loss for the recent quarter.

Coda Octopus Group, Inc. is a technology company operating through three primary segments: Marine Technology Business, Acoustic Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology segment develops and markets advanced underwater imaging and diving technologies, including the proprietary Echoscope® sonar series and DAVD diver display system. The PAL segment, acquired in 2024, specializes in acoustic sensors and materials serving diverse markets such as medical imaging and defense. The Defense Engineering Services segment provides design, engineering, manufacturing, and supply of proprietary sub-assemblies to prime defense contractors, often holding sole supplier status for the life of defense programs. The company operates internationally with a presence in the US, UK, Denmark, Australia, and India (dormant).

PURE BIOSCIENCE, INC. is focused on developing and commercializing proprietary antimicrobial products using its patented Silver Dihydrogen Citrate (SDC) technology. SDC is a stabilized ionic silver complex with broad-spectrum antimicrobial efficacy, low toxicity, and resistance to bacterial adaptation. The company offers a range of products including PURE® Hard Surface disinfectant and sanitizer, PURE Control® food contact processing aid, and other cleaning and personal care formulations. These products are registered with regulatory agencies such as the EPA and FDA and serve industries including food processing, food service, healthcare, facility care, transportation, and personal care. PURE BIOSCIENCE sells directly and through distributors, aiming to expand market reach and product adoption. The company holds multiple patents and trademarks to protect its technology and brands. Financially, the company has a history of losses and limited liquidity, with recent revenue of $443,000 and net losses continuing. It requires additional capital to sustain operations and execute its business plan.

Value Line, Inc. is a New York-based company founded in 1982 that produces investment periodicals, proprietary research, and licenses its intellectual property for use in third-party managed investment products. Its publishing subsidiary, Value Line Publishing LLC, offers a range of investment research products including comprehensive periodicals, niche newsletters, investment analysis software, and financial databases. The company markets its products under well-known brands such as The Value Line Investment Survey and Value Line Select. Value Line also holds a significant non-voting profits interest in EULAV Asset Management Trust (EAM), which manages the Value Line Funds, providing investment management and distribution services. The company’s revenues are derived from publishing subscriptions, licensing fees, and its interests in EAM. Digital offerings and data services complement traditional print products. The company faces competition from larger firms and free online information sources and acknowledges risks related to market conditions, regulatory changes, and subscriber retention [S1][S2].

Northern Minerals & Exploration Ltd. is an emerging natural resource company engaged in oil and gas production in central Texas and exploration for gold and silver in northern Nevada. The company began recognizing revenue from oil and gas sales in the fourth quarter of fiscal year 2025 through its investment in Lost Creek Acquisitions LLC. NMEX has also invested in Bitcoin and announced plans to begin Bitcoin mining. The company has increased its ownership in the West Lenapah Gas Project and continues to provide updates on its mineral properties. Financially, NMEX has reported net losses and maintains a low liquidity position, with current liabilities significantly exceeding current assets as of January 31, 2026. The company has several outstanding loans, including a defaulted promissory note and a line of credit with a former director. NMEX has indicated the need to raise additional funds through equity or debt financing to support its budgeted expenses and ongoing operations.

Clene Inc. is a clinical-stage pharmaceutical company focused on developing clean-surfaced nanotechnology (CSN®) therapeutics. These therapeutics consist of transition element nanocrystals with high catalytic activity that support cellular metabolic and energetic functions, particularly targeting neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease (PD). The company’s proprietary electro-crystal-chemistry platform produces nanocrystals free of chemical surface modifications, enhancing catalytic activity and reducing toxicity compared to traditional nanoparticles. Clene’s lead drug candidate, CNM-Au8, is a gold nanocrystal suspension undergoing multiple clinical trials and expanded access programs. The company also develops other therapeutic candidates and markets dietary supplements through its subsidiary and licensing agreements. Clene’s business strategy emphasizes innovation, first-mover advantage, broad applicability, and flexibility in nanocrystal design. The company collaborates with academic and clinical partners and outsources clinical trial management to CROs while maintaining oversight. Financially, Clene reported minimal revenue and significant net losses for the year ended December 31, 2025, with liquidity challenges and ongoing cash burn [S1].

X4 Pharmaceuticals operates as a single segment biopharmaceutical company specializing in rare hematology diseases. Its lead product, mavorixafor (XOLREMDI®), is FDA-approved for WHIM syndrome and is under pivotal Phase 3 evaluation for chronic neutropenia. The company has strategically restructured to focus resources on mavorixafor development, including workforce reductions and facility closures. Commercial launch of XOLREMDI began in mid-2024 in the US, with licensing agreements in place for Europe and other territories. The company’s revenue streams include product sales and license fees, with ongoing clinical trials and regulatory activities shaping its development pipeline.

Mechanics Bancorp is a bank holding company operating primarily through Mechanics Bank, serving customers mainly in California, Washington, Oregon, and Hawaii. The company provides banking and mortgage origination and servicing products. It is subject to extensive regulatory oversight, including capital adequacy and dividend restrictions. The company’s financial condition as of December 31, 2025, includes strong liquidity with over $1 billion in cash and cash equivalents and reported net income of $265.7 million. Mechanics Bancorp has announced significant dividends in recent years, reflecting its capital distribution policy. The company faces operational risks related to integration following a merger, interest rate sensitivity, geographic concentration, and reliance on technology and third-party service providers.

Ethos Technologies Inc. is a technology company focused on transforming the life insurance industry through a fully digital, vertically integrated platform. The platform simplifies the insurance value chain from distribution to underwriting, activation, payments, and administration. It serves consumers by providing a streamlined digital application and underwriting process, agents by offering tools to increase sales efficiency and payment speed, and carriers by expanding their market reach without Ethos assuming insurance risk. The company operates primarily through two distribution channels: direct-to-consumer and third-party agents. As of December 31, 2025, Ethos had activated over 500,000 policies and had over 15,000 active selling agents. The company completed its initial public offering in January 2026.

McEwen Inc. is a publicly traded company engaged in precious metals mining and exploration activities. The company reported $64.6 million in revenue and $38.1 million in net income for the fiscal year ended December 31, 2025. It maintains a solid liquidity position with a current ratio of 1.69 and cash ratio of 1.13. The company has recently expanded its mining asset base through acquisitions, including the consolidation of the Gold Bar Mine Complex in Nevada. McEwen also reported meaningful drilling results at its Tartan Mine Project. The company has a cybersecurity risk management framework led by its Director of IT and overseen by the Audit Committee of the Board of Directors.

NAPC Defense, Inc. is a defense-focused company specializing in tactical systems, notably the CornerShot USA product line. The company has transitioned from its prior identity as Treasure & Shipwreck Recovery through a merger and acquisition with Native American Pride Constructors, LLC. It operates primarily in the United States with expanding international interest, particularly in the Middle East. The company has secured multiple contracts, including a significant $38 million award, and engages in partnerships to market security products domestically and globally. Financial disclosures indicate modest revenue with net losses and liquidity challenges as of early 2026.

PharmaCyte Biotech, Inc. operates in the biotechnology sector, focusing on the research and development of cellular therapies for cancer treatment. Its lead product candidate targets locally advanced pancreatic cancer (LAPC), currently under clinical hold by the FDA pending regulatory and manufacturing milestones. The company has no commercial products or revenues to date and relies on strategic investments, collaborations, and capital raises to fund operations. PharmaCyte has invested in other biotech companies such as Femasys Inc. and TNF Pharmaceuticals, Inc., acquiring convertible securities and warrants that provide potential equity upside and board influence. The company maintains liquidity through cash reserves and short-term investments but faces challenges including regulatory approvals, supply chain dependencies on third-party manufacturers, and Nasdaq listing compliance risks. Leadership changes have occurred recently, with an interim CEO appointed in 2022. PharmaCyte's business model centers on advancing its cellular therapy candidates through clinical development and regulatory pathways while leveraging strategic investments and partnerships to enhance its technology portfolio and financial position.

EVENTIKO INC. is an early-stage company with no reported revenue or operating business activities as of the latest SEC filings through January 31, 2026. The company has no employees other than its officer and director and has incurred operating losses primarily related to general and administrative expenses. It has no current assets and a negative working capital position, financed mainly through director loans and equity issuances. The company does not currently offer employee benefit plans and has no off-balance sheet arrangements. The financial statements are prepared on a going concern basis, but the company anticipates the need for additional capital to sustain and expand operations.

Zeo ScientifiX, Inc. is a company engaged in the development and sale of allogenic aesthetic biologic products and a proprietary PPX™ service platform, targeting medical practice groups and distributors. The company’s revenues have shown growth driven by the PPX™ platform, while revenues from higher concentration biologics have declined due to increased market competition. The company operates with non-exclusive sales and supply agreements, reducing dependency on single customers or suppliers. It maintains finance leases for laboratory equipment and leases administrative facilities on a month-to-month basis. The company’s common stock is traded on the OTCQB market under the ticker ZEOX, with limited and sporadic trading activity.

Ocean Power Technologies, Inc. develops autonomous maritime systems, including PowerBuoy® technology, aimed at energy generation and maritime security applications. The company operates primarily in the United States and has expanded its market presence into Latin America through reseller agreements. It is listed on the NYSE American exchange under the ticker OPTT. The company faces operational challenges related to converting backlog into revenue and managing cash flow and financing needs. It is actively adopting artificial intelligence technologies to improve competitiveness and operational efficiency.

Trio Petroleum Corp is a California-headquartered oil and gas exploration and development company with operations in Monterey County, California; Uintah County, Utah; and Lloydminster, Saskatchewan, Canada. The company initially focused on California assets, including the South Salinas Project and McCool Ranch Oil Field, but has shifted toward more economically viable projects in Utah and Canada due to rising costs and regulatory challenges in California. Trio Petroleum holds a significant working interest in the South Salinas Project and has acquired producing heavy oil assets in Saskatchewan from Novacor and Capital Land. The company also holds an option to acquire 2,000 acres at P.R. Spring, Utah, contingent on production milestones. It is pursuing a Carbon Capture and Storage project at South Salinas to reduce carbon emissions. The company has generated revenue since early 2024 but continues to report net losses and faces liquidity constraints, with ongoing efforts to secure capital and strategic partnerships.

SafeSpace Global Corporation is a technology-driven enterprise delivering multimodal AI safety solutions designed to enhance resident safety, reduce injury risks, and improve care efficiency. Its product suite includes AI-powered fall monitoring, facial recognition access control, staff compliance tracking, wander protection, rapid video investigations, and school safety monitoring with real-time weapons detection. The company operates globally with offices in the US, Europe, Singapore, and India, and has recently expanded its operational infrastructure with a new office in Nashville. SafeSpace Global transitioned from pre-revenue to active revenue generation with initial contracts in senior living facilities and maintains partnerships to scale its platform. The company is led by experienced executives and supported by a growing team of AI specialists and engineers focused on accelerating product innovation and market deployment.

Silexion Therapeutics Corp is a clinical-stage biopharmaceutical company developing RNAi-based therapeutics, specifically small interfering RNAs (siRNAs) targeting oncogenic KRAS mutations G12D and G12V. The company's lead product candidate, SIL204, is designed for locally administered treatment of KRAS-driven cancers such as pancreatic and lung cancers. Silexion has completed multiple preclinical studies demonstrating positive efficacy data and has advanced SIL204 towards Phase 2/3 clinical trials, with toxicology studies completed and clinical trials planned to begin in Q2 2026. The company has entered a strategic collaboration with Catalent to support development and manufacturing. Silexion has no approved products or revenue and finances its operations primarily through equity sales and grants. As of December 31, 2025, the company had $6.0 million in cash and cash equivalents and reported net losses of $11.9 million for the year. The company faces typical early-stage biopharmaceutical risks including regulatory, funding, and competitive challenges.

Vireo Growth Inc. is a holding company operating in the cannabis sector through its subsidiaries in various U.S. states. The company’s operations are subject to extensive and complex regulatory regimes at federal, state, and local levels, which impose significant compliance costs and operational challenges. Vireo Growth relies on management agreements with third-party license holders in some states, exposing it to regulatory and counterparty risks. The company faces limited access to traditional banking and financing due to federal cannabis illegality, relying on a small number of financial institutions under stringent anti-money laundering regulations. Financially, Vireo Growth has incurred net losses in recent years and carries substantial secured indebtedness, which may constrain operational flexibility. The company is actively pursuing growth through acquisitions and a business combination with Eaze Inc., involving stock issuance and potential earnouts. Completion of certain asset sales and regulatory approvals remains uncertain, posing risks to operations and financial condition.

Auburn National Bancorporation, Inc. is a bank holding company headquartered in Auburn, Alabama, controlling AuburnBank, which operates primarily in East Alabama. The Bank has full-service branches in several local cities and a loan production office. The company’s business is influenced by local economic conditions, including the automotive industry and other major employers such as education and healthcare. It competes with numerous local, regional, and national banks, as well as nonbank financial service providers. The company pursues organic growth through loan growth and may consider acquisitions, though such activities carry integration and credit risks. Technological changes and cybersecurity risks are significant considerations. The company’s financial performance in recent years shows growth in net earnings and net interest income, with stable dividend payments. Capital adequacy and liquidity are maintained above regulatory requirements, supported by access to Federal Home Loan Bank advances and federal funds lines. The company’s loan portfolio is managed with credit risk policies and collateral guidelines. Risks include economic fluctuations, interest rate changes, competition, regulatory changes, cybersecurity threats, and operational risks.

Cibus, Inc. operates in the agricultural biotechnology sector, leveraging proprietary gene editing technology to develop plant traits that improve crop productivity, sustainability, and adaptability. Its core technology, the Rapid Trait Development System™ (RTDS®), enables rapid and precise editing of elite seed genetics. The company primarily licenses these traits to seed companies, receiving royalties based on trait usage. Its initial focus is on herbicide tolerance traits in rice, targeting markets in the United States, Latin America, and Asia. Cibus also pursues sustainable ingredient development, including bio-based fragrances, supported by partnerships with consumer goods companies. The company faces a complex regulatory landscape, with favorable developments in the Americas and evolving frameworks in the European Union. Cibus has been streamlining operations to focus resources on near-term commercial opportunities and reduce cash burn. Despite significant net losses and liquidity constraints, the company continues to invest in R&D and commercial advancement of its trait portfolio.

AXT INC operates in the semiconductor equipment and materials industry, focusing on the production of specialty material substrates including indium phosphide, gallium arsenide, and germanium wafers. These substrates serve applications in telecommunications, LEDs, lasers, and solar cells. The company also sells raw materials such as purified gallium and pBN crucibles through consolidated subsidiaries and joint ventures in China. Manufacturing is centralized in China to leverage cost advantages. The company’s revenue is predominantly generated from international customers, with China representing the largest geographic segment. Recent years have seen revenue fluctuations influenced by trade tariffs, export permit requirements, and changes in demand for specific wafer types. The company completed a significant stock offering in late 2025 to bolster liquidity. Operating results have been impacted by geopolitical and regulatory factors, as well as manufacturing utilization and product quality challenges.

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing a patented systemically-administered immunotherapy platform based on attenuated and killed Gram-negative bacteria designed to activate both innate and adaptive immune responses. The lead candidate, Decoy20, is undergoing Phase 1 clinical trials targeting advanced solid tumors, including monotherapy and combination studies with the anti-PD-1 antibody Tislelizumab. The company has completed cGMP manufacturing of Decoy20 and has enrolled multiple participants in its clinical trials, observing early signs of potential clinical benefit and manageable safety profiles. Indaptus has paused enrollment in its combination study and currently has no plans to initiate new clinical trials. The company has no approved products or revenues and funds operations primarily through equity and debt financings. Recent capital raises include convertible promissory notes and warrants, and a reverse stock split was implemented to meet Nasdaq listing requirements. Significant changes in management and board composition have occurred, with David Lazar appointed Co-CEO and Chairman, holding significant voting control through preferred stock convertible to common stock. The company faces typical risks of clinical-stage biotechs, including regulatory, financial, and operational uncertainties.

Crimson Wine Group, Ltd operates in the wine industry with two primary business segments: Wholesale and Direct to Consumer. The Wholesale segment sells wine to distributors under purchase orders, recognizing revenue upon shipment, and pays depletion allowances based on distributor sales. The Direct to Consumer segment sells wine through wine clubs, tasting rooms, and Ecommerce channels. The company also generates revenue from bulk wine and grape sales, custom winemaking services, and events. In 2025, the company faced declines in net sales across all segments, impacted by lower shipment volumes, distributor inventory management, and trade policy changes affecting exports. Despite these challenges, the company maintained gross margin percentages in wholesale and improved direct to consumer margins slightly. Operating expenses were managed down in response to market conditions. The company has a revolving credit facility and completed an asset acquisition in early 2026. Liquidity remains strong with substantial cash and current assets relative to liabilities. The company is exposed to risks from trade policy changes and customer concentration.

Brilliant Earth Group, Inc. is a global leader in ethically sourced fine jewelry, offering a broad collection of premium diamond engagement rings, wedding bands, gemstone rings, and fine jewelry. Founded in 2005 as an e-commerce company, it has expanded to a digitally native omnichannel model with 42 showrooms across the U.S. and sales to customers in over 50 countries. The company leverages proprietary technology including augmented reality try-on, blockchain-verified diamond traceability, and rapid fulfillment of made-to-order products. Its mission centers on creating a transparent, sustainable, compassionate, and inclusive jewelry industry, appealing strongly to Millennial and Gen Z consumers. The asset-light operating model features a virtual inventory and appointment-driven showrooms, supporting negative working capital and capital efficiency. The company continues to invest in brand awareness, showroom expansion, product assortment, and international growth.

GitLab Inc. operates an intelligent orchestration platform for DevSecOps, designed to unify software development, operations, IT, security, and business teams across the entire software development lifecycle. The platform leverages a unified data model and open-core business model, enabling customers and contributors to extend and customize functionality. GitLab serves a broad customer base, including over 50 million registered users and more than half of the Fortune 100 companies. The company offers flexible deployment options including self-managed, fully managed SaaS, and dedicated single-tenant SaaS solutions tailored for regulated industries. GitLab's platform integrates AI capabilities through its Duo Agent Platform, facilitating autonomous task execution across software lifecycle stages. The company employs a multi-tier subscription model with seat-based and usage-based pricing, including AI add-ons. Fiscal 2026 revenue reached $955.2 million, growing 26% year-over-year, with a net loss of $56.0 million. GitLab maintains strong liquidity with a current ratio of 2.54 as of January 31, 2026. The company emphasizes culture, innovation velocity, and a global partner ecosystem to support growth and customer expansion.

INTELLIGENT PROTECTION MANAGEMENT CORP. (IPM) provides a comprehensive suite of IT-related services primarily to enterprise and commercial clients across the United States, including managed IT security services, secure private cloud hosting, managed backup and disaster recovery, professional services, procurement services, and web hosting. The company also supports ManyCam software, a live streaming and virtual camera product. In January 2025, IPM completed the acquisition of Newtek Technology Solutions, significantly expanding its IT and cloud services offerings, while divesting its consumer-focused video and telecommunications software businesses. IPM operates secure private cloud hosting from Tier 3 data centers in Phoenix, Arizona, and Edison, New Jersey, employing advanced security and compliance measures. The company serves diverse industries such as finance, legal, healthcare, and manufacturing, emphasizing a consultative sales approach and strategic partnerships. IPM holds eight patents and continues to defend its intellectual property. The company reported $23.6 million in revenue for 2025, reflecting substantial growth post-acquisition, with ongoing investments in AI integration and new product development.

Ankam, Inc. develops and manages mobile applications, primarily Expense Minder and MoneySaverApp, aimed at streamlining expense reporting and financial management. The company has structured its operations through subsidiaries, including Ankam LLC and Mei Sheng Corporation Limited, to facilitate business activities and geographic expansion, particularly in Asia. It has acquired Apex Intelligence LLC to enhance its product offerings. The company employs digital marketing and app store optimization to grow its user base and plans advertising initiatives contingent on funding availability. Leadership changes and investor transactions have shaped its governance and ownership structure.

Phoenix Energy One, LLC, established in 2019, operates in the oil and gas sector with a strategy combining direct drilling operations, acquisition of royalty assets, and acquisition of non-operated working interests. The company’s direct drilling activities are concentrated in the Williston, Powder River, and Denver-Julesburg Basins, while its asset acquisitions span multiple U.S. basins. It has developed proprietary software to support asset identification and management. The company’s operations have expanded significantly since inception, with production volumes increasing from under 0.2 million Boe in 2020 to over 9.9 million Boe in 2025 and employee count growing from 21 to 206. Revenue is primarily derived from mineral and royalty payments and product sales of crude oil, natural gas, and NGL, with product sales becoming a larger portion of total revenue. The company also provides saltwater disposal and crude oil marketing services through subsidiaries. Capital expenditures and debt levels are substantial, reflecting growth and development activities.